MiNK Therapeutics (INKT)

• Market cap: $20.7M
• 1 day: 4.76%
• 5 days: -14.94%
• 1 month: -25.66%
• 3 months: -30.49%
• 6 months: -39.78%
• Year to date: -51.93%
• 1 year: -47.60%
• 5 years: -95.63%
• 10 years: -95.63%
• Sector: Healthcare
• Industry: Biological Products, Except Diagnostic Substances

About: MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing allogeneic invariant natural killer T-cell therapies to treat cancer and other life-threatening illnesses.

Employees: 37

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

0.45% less ownership

Funds ownership: 2.59% [Q2] → 2.14% (-0.45%) [Q3]

16% less funds holding

Funds holding: 31 [Q2] → 26 (-5) [Q3]

25% less capital invested

Capital invested by funds: $848K [Q2] → $632K (-$216K) [Q3]

29% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 7

56% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 9

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $4 663% upside
• Avg. target: $6.50 1,140% upside
• High target: $9 1,618% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

Baird Jack Allen 45% 1-year accuracy 5 / 11 met price target	663% upside $4	Outperform Maintained	15 Nov 2024
HC Wainwright & Co. Emily Bodnar 17% 1-year accuracy 26 / 150 met price target	1,618% upside $9	Buy Reiterated	15 Nov 2024